Advertisement

Sorafenib Delays Advanced Thyroid Cancer Growth — Physician’s First Watch

Medical News |
June 3, 2013

Sorafenib Delays Advanced Thyroid Cancer Growth

By Kelly Young

Sorafenib is associated with significantly longer progression-free survival in patients with metastatic thyroid cancer, according to interim results of a placebo-controlled, phase 3 study presented at the American Society of Clinical Oncology's annual meeting.

Roughly 420 patients with refractory differentiated thyroid cancer that had progressed in the past 14 months were randomized to placebo or sorafenib, which inhibits VEGFR1-3 and Raf kinases. Seventy percent of patients taking placebo switched to open-label sorafenib once their disease progressed. Sorafenib was associated with 10.8 months of progression-free survival, compared with 5.8 months in the placebo group.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement